The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative efficacy of antifungal prophylaxis in acute myeloid leukemia: A systematic review and meta-analysis.
 
Cameron Hunter
No Relationships to Disclose
 
Abdulrahman Alhajahjeh
No Relationships to Disclose
 
Niroop Rajashekar
No Relationships to Disclose
 
Alyssa Grimshaw
No Relationships to Disclose
 
Andrew Chou
No Relationships to Disclose
 
Heidi Roeder
No Relationships to Disclose
 
William Eighmy
No Relationships to Disclose
 
Lourdes Mendez
Consulting or Advisory Role - Amgen; Inventiva Pharma; Rigel
 
Maximilian Stahl
Consulting or Advisory Role - Boston Consulting Group; Clinical Care Options; Curis Oncology; GlaxoSmithKline; Haymarket; Kura Oncology; Kymera; Novartis; Sierra Oncology; Syndax
 
Nikolai Podoltsev
Consulting or Advisory Role - Abbvie; Amgen; Cycle Pharmaceuticals; Incyte; Karyopharm Therapeutics; Novartis; PhramaEssentia; Sobi; Syndax; Takeda
Research Funding - AI Therapeutics (Inst); Aptos Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Jazz Pharmaceuticals (Inst); Kartos Therapeutics (Inst); Karyophram Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaEssentia (Inst); Protagonist Therapeutics (Inst); Samus Therapeutics (Inst); Sunesis Pharmaceuticals (Inst)
Other Relationship - Cogent Biosciences
 
Amer Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Rory Shallis
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Geron; Gilead Sciences; Kura Oncology; Rigel; SERVIER; Syndax; TScan Therapeutics
Research Funding - Servier
 
Jan Philipp Bewersdorf
No Relationships to Disclose